Home / Knowledge Center /
Article

2019 Investments Centered around Cell and Gene Therapies

Previous investments set a foundation for later efficiency improvements.

In 2019, cold-chain service providers continued investments in platforms and services designed for gene and cell therapy clinical studies. Marken acquired a logistics firm in Japan, and expanded logistics operations in Philadelphia with a new GMP-compliant plant and liquid nitrogen storage facilities, says president Ariette Van Strien.

Read more on this article by clicking here.

View Resource

Our Expert

Please complete this form to view the Article

This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies